Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects

Lynne Krohn, Karl Heilbron, Cornelis Blauwendraat, Regina H. Reynolds, Eric Yu, Konstantin Senkevich, Uladzislau Rudakou, Mehrdad A. Estiar, Emil K. Gustavsson, Kajsa Brolin, Jennifer A. Ruskey, Kathryn Freeman, Farnaz Asayesh, Ruth Chia, Isabelle Arnulf, Joshua Shulman, Jacques Montplaisir, Jean‐François Gagnon, Alex Désautels, Yves Dauvilliers, Gian Luigi Gigli, Mariarosaria Valente, Francesco Janes, Andrea Bernardini, Birgit Högl, Ambra Stefani, Abubaker Ibrahim, Karel Šonka, David Kemlink, Wolfgang H. Oertel, Annette Janzen, Giuseppe Plazzi, Francesco Biscarini, Elena Antelmi, Michela Figorilli, Monica Puligheddu, Brit Mollenhauer, Claudia Trenkwalder, Friederike Sixel‐Döring, Valérie Cochen De Cock, Christelle Monaca, Anna Heidbreder, Luigi Ferini‐Strambi, Femke Dijkstra, Mineke Viaene, Beatriz Abril, Bradley F. Boeve, Stella Aslibekyan, Adam Auton, Elizabeth Babalola, Robert K. Bell, Jessica Bielenberg, Katarzyna Bryc, Emily Bullis, Daniella Coker, Gabriel Cuéllar-Partida, Devika Dhamija, Sayantan Das, Sarah L. Elson, Teresa Filshtein, Kipper Fletez‐Brant, Pierre Fontanillas, Will Freyman, Pooja Gandhi, Barry Hicks, David A. Hinds, Ethan M. Jewett, Yunxuan Jiang, Katelyn Kukar, Keng‐Han Lin, Maya Lowe, Jey C. McCreight, Matthew H. McIntyre, Steven J. Micheletti, Meghan E. Moreno, Joanna L. Mountain, Priyanka Nandakumar, Elizabeth S. Noblin, Jared O’Connell, Aaron A. Petrakovitz, G. David Poznik, Morgan Schumacher, Anjali J. Shastri, Janie F. Shelton, Jingchunzi Shi, Suyash Shringarpure, Vinh Tran, Joyce Y. Tung, Xin Wang, Wei Wang, Catherine H. Weldon, Peter Wilton, Alejandro Hernandez, Corinna Wong, Christophe Toukam Tchakouté, Sonja W. Scholz, Mina Ryten, Sara Bandrés‐Ciga, Alastair J. Noyce, Paul J. CannonNature Communications 2022 · DOI

TL;DR

This study identifies five new genetic risk loci for REM sleep behavior disorder (RBD), a key early symptom of neurodegenerative diseases like Parkinson's. By combining genome-wide association studies with gene expression analysis, the researchers found that specific genetic variants influence gene expression in the brain, potentially explaining how RBD develops and its link to other synucleinopathies.

What Problem Does This Paper Address?

REM sleep behavior disorder (RBD) is a fascinating condition where people physically act out their dreams. Crucially, it's a very early warning sign for neurodegenerative diseases characterized by alpha-synuclein protein buildup, such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB). While RBD is a strong predictor of these conditions and often indicates a more severe disease course, the underlying genetic mechanisms and how they contribute to the disease are not well understood. This lack of understanding hinders the development of early diagnostic tools and preventative treatments. This paper aims to shed light on the genetic architecture of RBD, identify specific genetic risk factors, and explore how these factors might influence gene expression in the brain, potentially offering a window into the earliest stages of synucleinopathies.

Methods

The researchers employed a multi-pronged approach:

  • Genome-Wide Association Study (GWAS): They conducted a large-scale GWAS by meta-analyzing data from two cohorts: one with idiopathic RBD (iRBD) and another with Parkinson's disease patients who also had probable RBD (PD+pRBD). This allowed them to scan the entire genome for genetic variants associated with RBD.
  • Expression Quantitative Trait Loci (eQTL) Analysis: They investigated how the identified genetic variants affect gene expression in various human tissues, particularly brain tissue, using data from the GTEx and PsychENCODE consortia. This helps link genetic risk to biological function.
  • Colocalization Analysis: This technique was used to determine if the same genetic variants are responsible for both RBD risk and altered gene expression in specific tissues.
  • Polygenic Risk Score (PRS) Analysis: They calculated a PRS for RBD to assess its predictive power in distinguishing RBD cases from controls and its ability to identify distinct genetic profiles.
  • Pathway Analysis: They used gene-set enrichment analysis to identify biological pathways that are over-represented among genes near the identified risk loci, offering insights into the biological mechanisms involved.
  • Genetic Correlation Analysis: They explored the genetic overlap between RBD and other traits and diseases, including other synucleinopathies, using LD-score regression.

Datasets

  • iRBD Cohort: 1061 cases and 8386 controls of European ancestry.
  • PD+pRBD Cohort: 1782 cases and 131,250 controls from 23andMe, Inc. (age and sex-matched).
  • Replication Cohort for PRS: 502 PD +/- pRBD cases and 907 controls from McGill University.
  • eQTL Data: GTEx v8 (human bulk-tissue RNA-sequencing) and PsychENCODE (adult human brain tissue RNA-sequencing).
  • Cell-type Specific eQTL Data: From Bryois et al. (human single-nucleus RNA-sequencing of the middle temporal gyrus from the Allen Institute for Brain Science).

Key Insights and Ideas

  • RBD has a distinct genetic signature: While RBD shares some genetic risk factors with PD and DLB, the study highlights that it also possesses unique genetic underpinnings, suggesting it's not just a symptom but a distinct subtype of synucleinopathy.
  • Gene expression in the brain is key: The identified genetic variants don't just confer risk; they actively influence the expression of genes in specific brain regions, particularly for the SNCA gene and its antisense transcript SNCA-AS1. This provides a direct link between genetics and the biological processes occurring in the brain.
  • The Autophagy-Lysosomal Pathway (ALP) is central: Pathway analysis strongly implicates the ALP in RBD pathogenesis, a pathway known to be involved in clearing misfolded proteins like alpha-synuclein. This is particularly interesting as it's a shared pathway with PD and DLB, but the specific genes highlighted in RBD point to a unique role.
  • SNCA-AS1 as a potential regulator: The study suggests that SNCA-AS1, an antisense RNA, might play a crucial role in regulating alpha-synuclein protein levels in the brain. Reduced expression of SNCA-AS1 could lead to increased alpha-synuclein, potentially contributing to neurodegeneration in specific brain regions.

Key Results

  • Five novel RBD risk loci identified: The study identified significant associations near the SNCA, GBA, TMEM175, INPP5F, and SCARB2 genes.
  • Differential gene expression in brain regions: Colocalization analyses revealed that variants associated with RBD show differential expression of SNCA-AS1 in various brain regions, with a particularly strong link in the cerebellum and frontal cortex.
  • RBD PRS is a good predictor: The calculated RBD polygenic risk score effectively differentiated RBD cases from controls, performing better than PD PRS for distinguishing PD-PRBD from controls.
  • Autophagy-Lysosomal Pathway enrichment: Pathway analysis highlighted the involvement of the ALP, including components like the lysosome and vacuole, in RBD.
  • Genetic correlation insights: While RBD shows some genetic overlap with PD, it appears to have a more distinct genetic profile compared to PD+pRBD, especially concerning other synucleinopathies.

Limitations and Future Work

  • Sample size limitations: Despite being the largest RBD GWAS to date, the sample size is still relatively small, meaning some associations might have been missed, and future larger studies are needed.
  • PD-skewed meta-analysis: The meta-analysis included a significant proportion of PD+pRBD cases, which might have skewed the results towards PD-specific signals and diluted iRBD-specific findings.
  • European ancestry focus: The study population was primarily of European ancestry, limiting the generalizability of findings to other populations. Future research should include diverse ancestries.
  • Potential for heterogeneity: The authors acknowledge potential heterogeneity between the iRBD and PD+pRBD cohorts, particularly at the SNCA locus.
  • Future directions: The authors suggest further investigation into the role of SNCA-AS1 as a regulator of alpha-synuclein expression and its impact on cognitive decline. They also propose exploring the autophagy-lysosomal pathway and GCase function as therapeutic targets for RBD and early synucleinopathies. Further studies are needed to confirm the differential effects of SNCA and SCARB2 variants in specific brain regions and to investigate the genetic architecture of RBD in diverse populations.

Summary updated

Abstract

Rapid-eye movement (REM) sleep behavior disorder (RBD), enactment of dreams during REM sleep, is an early clinical symptom of alpha-synucleinopathies and defines a more severe subtype. The genetic background of RBD and its underlying mechanisms are not well understood. Here, we perform a genome-wide association study of RBD, identifying five RBD risk loci near SNCA, GBA, TMEM175, INPP5F, and SCARB2. Expression analyses highlight SNCA-AS1 and potentially SCARB2 differential expression in different brain regions in RBD, with SNCA-AS1 further supported by colocalization analyses. Polygenic risk score, pathway analysis, and genetic correlations provide further insights into RBD genetics, highlighting RBD as a unique alpha-synucleinopathy subpopulation that will allow future early intervention.
BibTeX
@inproceedings{krohn2022genome,
  author = {Lynne Krohn and Karl Heilbron and Cornelis Blauwendraat and Regina H. Reynolds and Eric Yu and Konstantin Senkevich and Uladzislau Rudakou and Mehrdad A. Estiar and Emil K. Gustavsson and Kajsa Brolin and Jennifer A. Ruskey and Kathryn Freeman and Farnaz Asayesh and Ruth Chia and Isabelle Arnulf and Joshua Shulman and Jacques Montplaisir and Jean‐François Gagnon and Alex Désautels and Yves Dauvilliers and Gian Luigi Gigli and Mariarosaria Valente and Francesco Janes and Andrea Bernardini and Birgit Högl and Ambra Stefani and Abubaker Ibrahim and Karel Šonka and David Kemlink and Wolfgang H. Oertel and Annette Janzen and Giuseppe Plazzi and Francesco Biscarini and Elena Antelmi and Michela Figorilli and Monica Puligheddu and Brit Mollenhauer and Claudia Trenkwalder and Friederike Sixel‐Döring and Valérie Cochen De Cock and Christelle Monaca and Anna Heidbreder and Luigi Ferini‐Strambi and Femke Dijkstra and Mineke Viaene and Beatriz Abril and Bradley F. Boeve and Stella Aslibekyan and Adam Auton and Elizabeth Babalola and Robert K. Bell and Jessica Bielenberg and Katarzyna Bryc and Emily Bullis and Daniella Coker and Gabriel Cuéllar-Partida and Devika Dhamija and Sayantan Das and Sarah L. Elson and Teresa Filshtein and Kipper Fletez‐Brant and Pierre Fontanillas and Will Freyman and Pooja Gandhi and Barry Hicks and David A. Hinds and Ethan M. Jewett and Yunxuan Jiang and Katelyn Kukar and Keng‐Han Lin and Maya Lowe and Jey C. McCreight and Matthew H. McIntyre and Steven J. Micheletti and Meghan E. Moreno and Joanna L. Mountain and Priyanka Nandakumar and Elizabeth S. Noblin and Jared O’Connell and Aaron A. Petrakovitz and G. David Poznik and Morgan Schumacher and Anjali J. Shastri and Janie F. Shelton and Jingchunzi Shi and Suyash Shringarpure and Vinh Tran and Joyce Y. Tung and Xin Wang and Wei Wang and Catherine H. Weldon and Peter Wilton and Alejandro Hernandez and Corinna Wong and Christophe Toukam Tchakouté and Sonja W. Scholz and Mina Ryten and Sara Bandrés‐Ciga and Alastair J. Noyce and Paul J. Cannon},
  title = {{Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-34732-5},
}
Figure